Global Multiple Sclerosis Therapeutics to 2019: Worldwide Scenario, Trends, Industry Analysis, Size, Share and Forecast Report Available Online by Researchmoz.us

Share Article

ResearchMoz.us includes new market research report "Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth" to its huge collection of research reports.Browse all GBI Research Market Research Reports at http://www.researchmoz.us/publisher/gbi-research-2.html.

ResearchMoz

ResearchMOZ

Global Multiple Sclerosis Therapeutics to 2019: Worldwide Scenario, Trends, Industry Analysis, Size, Share And Forecast Report Available Online by Researchmoz.us

Multiple Sclerosis Therapeutics Market report is designed for clients needing a quality in-depth understanding of the Multiple Sclerosis Therapeutics Market report. These reports provide a much more granular and detailed data set than our competitors. All data have been researched, brand upwards, by an experienced ''on-the-ground'' industry analyst who conducts face-to-face interviews with key producers, leading companies in allied industries, distributors and retailers.

Full Report with TOC @ http://www.researchmoz.us/multiple-sclerosis-therapeutics-to-2019-treatment-diversification-increasing-efficacy-and-pipeline-innovation-combine-to-drive-growth-report.html.

GBI Research, the leading business intelligence provider, has released its latest research, “Multiple Sclerosis Therapeutics to 2019 Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth”. Currently there are a number of disease-modifying drugs in the Multiple Sclerosis (MS) market that are indicated for the treatment of relapsing forms of the disease, specifically reducing the frequency of disease relapses. The market is led by Copaxone, which achieved global sales of $4 billion in 2012. Over the forecast period 2012–2019, a variety of new drugs are due to enter the market that will offer a vast improvement in efficacy but also convenience, as many of these drugs are orally administered. Additionally, a high number of monoclonal Antibodies (mAbs) are due to enter the market and diversify it in terms of its portfolio for late stage or aggressive MS. All of these drugs have been shown to offer substantial improvements over current therapies. The price of these new therapies is expected to be high, particularly for the mAbs, but this is unlikely to hinder their uptake. As a result of this, as well as an overall increase in the treated population, GBI Research believes the global market has the potential to grow to a value of $17.9 billion by 2019.

Browse Global Telemedicine and M-Health Convergence Market - http://www.researchmoz.us/telemedicine-and-m-health-convergence-market-shares-strategies-and-forecasts-worldwide-2013-to-2019-report.html

Scope

A brief introduction to MS, including the disease’s history, pathogenesis, risk factors and diagnosis.
In-depth analysis of the eight major disease-modifying drugs for MS, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map comparing the drugs in terms of safety and efficacy.
Comprehensive review of the pipeline for MS therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes.
Additional analysis of pipeline drug clinical trials by phase, molecule type, trial size and trial duration.
Multi-scenario forecast model of the market, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology.
Discussion of the drivers and barriers for market growth or decay.

Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html.

Reasons to buy

Understand the different levels of MS therapies, from early-stage/mild MS to late-stage/aggressive MS.
Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent.
Observe the trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for multiple sclerosis therapeutics.
Observe the shift in clinical trial endpoints with clinical phase, and use this data to potentially influence any future developmental programs.
Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the multiple sclerosis therapeutics market.

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7

2 Introduction 8
2.1 Disease Overview 8
2.2 Epidemiology 8
2.3 Symptoms 9
2.4 Etiology 9
2.5 Pathophysiology 10
2.5.1 Blood Brain Barrier Degradation 10
2.5.2 Cellular Infiltration of the Central Nervous System 10
2.6 Co-morbidities/Complications 11
2.7 Diagnosis 12
2.7.1 McDonald Criteria 12
2.7.2 Physical Examination 13
2.7.3 MRI Scans 13
2.7.4 Lumbar Puncture 13
2.7.5 Other Diagnostic Tests 13
2.8 Prognosis 14
2.9 Treatment Efficacy 15
2.10 Treatment Options 15

Browse All Countrywise Report @ http://www.researchmoz.us/country.html.

List of Figures

Figure 1: Treatment Algorithm, Global, Multiple Sclerosis, 2013 18
Figure 2: Multiple Sclerosis, Marketed Products Heat Map 27
Figure 3: Overall Pipeline for Multiple Sclerosis 30
Figure 4: Routes of Administration in the Pipeline 31
Figure 5: Molecular Targets of Pipeline Molecules 32
Figure 6: Molecular Targets in MS Pipeline by Phase of Development 33
Figure 7: Failure Rate of MS Clinical Trials, 2006–2013 35
Figure 8: Reasons for Clinical Trial Failure, 2006–2013 36
Figure 9: Clinical Trial Size by Product and Phase, 2006–2013 37
Figure 10: Clinical Trial Duration by Phase and Molecule Type, 2006–2013 39
Figure 11: Multiple Sclerosis, Pipeline Product Heat Map 45
Figure 12: Multiple Sclerosis, Marketed Product Heat Map, 2012–2019 46
Figure 13: Multiple Sclerosis Market, Global, Patient Volumes (‘000) and Market Size ($bn), 2012–2019 49

####

Related Report

1) Narcolepsy Global Clinical Trials Review, H2, 2013

Narcolepsy Global Clinical Trials Review, (http://www.researchmoz.us/narcolepsy-global-clinical-trials-review-h2-2013-report.html) H2, 2013" provides data on the Narcolepsy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Narcolepsy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Narcolepsy. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

2) Bacteriuria Global Clinical Trials Review, H2, 2013

Bacteriuria Global Clinical Trials Review, (http://www.researchmoz.us/bacteriuria-global-clinical-trials-review-h2-2013-report.html) H2, 2013" provides data on the Bacteriuria clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bacteriuria. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bacteriuria. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

3) Osteoporosis Global Clinical Trials Review, H2, 2013

Osteoporosis Global Clinical Trials Review, (http://www.researchmoz.us/osteoporosis-global-clinical-trials-review-h2-2013-report.html) H2, 2013" provides data on the Osteoporosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Osteoporosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Osteoporosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

About Us

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:
Email: sales(at)researchmoz(dot)us
WebSite: http://www.researchmoz.us/

Visit Blog @ http://industryresearchnews.blogspot.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michell Thoras
ResearchMoz
+1-518-618-1030
Email >
Follow us on
Visit website